Live tape
Top 8, mentions 7d2,137GOOGL453 mentions▲ +0.06NVDA345 mentions▲ +0.07META271 mentions▲ +0.05QQQ266 mentions▲ +0.09SPY256 mentions▲ +0.04AAPL193 mentions▲ +0.04MSFT178 mentions▲ +0.06TSLA175 mentions▲ +0.06

Equity · Healthcare

INBX

Inhibrx Biosciences, Inc. · NasdaqGS

$87 −2.25% 1D Finazon · prior-day close · Jul 17, 2026
Price · Chart
Our own end-of-day closes 19 sessions
$105 $85 22 Jun 17 Jul

The line runs $93 on 22 June through $87 on 17 July, on a scale from $85 to $105. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of INBX over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 19 sessions over that window: $93 on 22 June 2026 through $87 on 17 July 2026.

Market cap $1.3B
52-week range $21 – $142
Avg volume 83.9K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Sep 20, 2026

INBX insider trades

SEC Form 4 · last 90 days · newest reported trade 16 Sep 2026
Open-market buys 4
Open-market sells 5
Net bought $3.72M
Non-trade filings 0
Date Insider Type Shares Value
16 Sep 2026 Kayyem Jon Faiz Director Buy 5,000 $500K
15 Sep 2026 MANHARD KIMBERLY Director Sell 500 $53K
14 Sep 2026 MANHARD KIMBERLY Director Sell 500 $55K
11 Sep 2026 MANHARD KIMBERLY Director Sell 500 $56K
09 Sep 2026 MANHARD KIMBERLY Director Sell 500 $58K
08 Sep 2026 FORSYTH DOUGLAS Director Buy 2,500 $287K
08 Sep 2026 Lappe Mark Chief Executive Officer Buy 25,000 $2.65M
08 Sep 2026 Kayyem Jon Faiz Director Buy 5,000 $568K
08 Sep 2026 MANHARD KIMBERLY Director Sell 500 $58K

INBX reported financials

SEC EDGAR XBRL

INBX reported revenue of $1.3M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$140.1M.

Figure Reported Period
Revenue $1.3M 31 Dec 2025 fiscal year
Net income −$140.1M 31 Dec 2025 fiscal year
Diluted EPS −$9.04 31 Dec 2025 fiscal year
Total assets $154.2M 30 Jun 2026 at period end
Total equity −$53.0M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

INBX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-2.34 —
31 Mar 2026 Q1 2026 $-2.15 —
31 Dec 2025 FY 2025 $-9.04 $1M
30 Sep 2025 Q3 2025 $-2.28 —
30 Jun 2025 Q2 2025 $-1.85 $1M
31 Mar 2025 Q1 2025 $-2.80 —
31 Dec 2024 FY 2024 $112.62 $0M
30 Sep 2024 Q3 2024 $-2.84 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

INBX institutional holders

SEC Form 13F

8 of the 45 institutional funds we track reported a INBX position for the quarter ended 30 Jun 2026 — a combined $133.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Viking Global Investors Held (±25%) −21.8% shares 1,123,929 $106.5M
Millennium Management Trimmed −55.1% shares 147,200 $13.9M
Renaissance Technologies Held (±25%) +23.9% shares 62,201 $5.9M
Point72 Asset Management New position 26,011 $2.5M
D. E. Shaw & Co. Trimmed −71.2% shares 22,322 $2.1M
AQR Capital Management Added +34.2% shares 11,247 $1.1M
Marshall Wace Trimmed −57.9% shares 8,800 $834K
Balyasny Asset Management New position 4,728 $448K
Citadel Advisors Exited
Tudor Investment Corp Exited

Source: SEC EDGAR 13F filings

INBX fails-to-deliver

SEC CNS data

On 27 Aug 2026, 61 shares of INBX failed to deliver (about $8K).

Settlement date Shares failed Notional % of shares out
27 Aug 2026 61 $8K <0.001%
20 Aug 2026 2 $203 <0.001%
14 Aug 2026 14 $1K <0.001%

Source: SEC fails-to-deliver (CNS) data